Efficacy and Adverse Events Associated With Use of OnabotulinumtoxinA for Treatment of Neurogenic Detrusor Overactivity: A Meta-Analysis

Efficacy and Adverse Events Associated With Use of OnabotulinumtoxinA for Treatment of Neurogenic Detrusor Overactivity: A Meta-Analysis

Purpose OnabotulinumtoxinA is used widely for the treatment of neurogenic detrusor overactivity. We conducted a systematic review and meta-analysis to assess its efficacy and safety for neurogenic detrusor overactivity treatment. Methods A systematic literature review was performed to identify all p...

Full description

Bibliographic Details
Main Authors:	Hejia Yuan, Yuanshan Cui, Jitao Wu, Peng Peng, Xujie Sun, Zhenli Gao
Format:	Article
Language:	English
Published:	Korean Continence Society 2017-03-01
Series:	International Neurourology Journal
Subjects:	Neurogenic Detrusor Overactivity OnabotulinumtoxinA Meta-Analysis Randomized Controlled Trial
Online Access:	http://www.einj.org/upload/pdf/inj-1732646-323.pdf

Similar Items

Efficacy and Safety of OnabotulinumtoxinA in Treating Neurogenic Detrusor Overactivity: A Systematic Review and Meta-analysis
by: Xin Zhou, et al.
Published: (2015-01-01)

Efficacy and Safety of OnabotulinumtoxinA in Patients With Neurogenic Detrusor Overactivity Caused by Spinal Cord Injury: A Systematic Review and Meta-analysis
by: Guang-Ping Li, et al.
Published: (2018-12-01)

Efficacy and Safety of Intravesical OnabotulinumtoxinA Injection in Patients with Detrusor Hyperactivity and Impaired Contractility
by: Chung-Cheng Wang, et al.
Published: (2016-03-01)

Trigonal-Sparing vs. Trigonal-Involved OnabotulinumtoxinA Injection for the Treatment of Overactive Bladder: A Systematic Review and Meta-Analysis
by: Yuanshan Cui, et al.
Published: (2021-10-01)

A Korean Postmarketing Study Assessing the Effectiveness of OnabotulinumtoxinA for the Treatment of Neurogenic Detrusor Overactivity or Idiopathic Overactive Bladder Using a Validated Patient-Reported Outcome Measure
by: Kwang Jin Ko, et al.
Published: (2019-03-01)

The effect of spinal cord-injury level on the outcome of neurogenic bladder treatment using OnabotulinumtoxinA
by: Waleed Al Taweel, et al.
Published: (2015-01-01)

Effectiveness and Safety of Intradetrusor OnabotulinumtoxinA Injection for Neurogenic Detrusor Overactivity and Overactive Bladder Patients in Taiwan—A Phase IV Prospective, Interventional, Multiple-Center Study (Restore Study)
by: Chung-Cheng Wang, et al.
Published: (2021-12-01)

Retrospective Observational Study of Treatment Patterns and Efficacy of onabotulinumtoxinA Therapy in Patients with Refractory Overactive Bladder in Clinical Practice
by: Kwang Jin Ko, et al.
Published: (2023-05-01)

Therapeutic outcome and patient adherence to repeated onabotulinumtoxinA detrusor injections in chronic spinal cord-injured patients and neurogenic detrusor overactivity
by: Sheng-Fu Chen, et al.
Published: (2015-07-01)

A Feasibility Study to Evaluate Changes in Urinary Metabolites after OnabotulinumtoxinA Injection for Refractory Overactive Bladder
by: Laura M. Tellechea, et al.
Published: (2022-09-01)

Low dose intradetrusor injections of onabotulinumtoxinA in women with overactive bladder symptoms or the painful bladder syndrome: unfavorable balance between clinical efficacy and the need for catheterization
by: Jan Groen, et al.
Published: (2012-10-01)

Short-term outcome of onabotulinumtoxin A injection for the treatment of refractory idiopathic detrusor overactivity
by: Gamal E A. Abourjila, et al.
Published: (2020-01-01)

FREQUENCY OF DETRUSOR LEAK POINT PRESSURES AMONGST PATIENTS WITH URODYNAMIC DIAGNOSIS OF DETRUSOR OVERACTIVITY
by: Nadeem Ahmad, et al.
Published: (2019-08-01)

Intravesical OnabotulinumtoxinA Injection for Overactive Orthotopic Ileal Neobladder: Feasibility and Efficacy
by: Nathan Hoag, et al.
Published: (2016-03-01)

Effect of Bladder Injection of OnabotulinumtoxinA on the Central Expression of Genes Associated with the Control of the Lower Urinary Tract: A Study in Normal Rats
by: Soultana Markopoulou, et al.
Published: (2022-11-01)

Low dose intradetrusor injections of onabotulinumtoxina in women with overactive bladder symptoms or the painful bladder syndrome: unfavourable balance between clinical efficacy and the need for catheterisation
by: Jan Groen, et al.
Published: (2012-01-01)

OnabotulinumtoxinA: Still the Present for Chronic Migraine
by: Carlo Baraldi, et al.
Published: (2023-01-01)

Molecular Mechanism Operating in Animal Models of Neurogenic Detrusor Overactivity: A Systematic Review Focusing on Bladder Dysfunction of Neurogenic Origin
by: Ana Ferreira, et al.
Published: (2023-02-01)

Botulinum Toxin A Injection for Autonomic Dysreflexia—Detrusor Injection or Urethral Sphincter Injection?
by: Po-Ming Chow, et al.
Published: (2023-01-01)

Pericranial Muscle Stiffness, Pain Thresholds, and Tenderness during a Treatment Cycle of OnabotulinumtoxinA for Chronic Migraine Prevention
by: Sebastian Worsaae Dalby, et al.
Published: (2024-02-01)

Safety of OnabotulinumtoxinA in the [management of] chronic migraine in pregnancy
by: Liza Smirnoff
Published: (2022-08-01)

Real-world effectiveness, satisfaction, and optimization of ubrogepant for the acute treatment of migraine in combination with onabotulinumtoxinA: results from the COURAGE Study
by: Aubrey Manack Adams, et al.
Published: (2023-08-01)

Clinical outcomes of botulinum toxin A management for neurogenic detrusor overactivity: meta-analysis
by: Shang-Jun Wu, et al.
Published: (2019-01-01)

Real Life Data on OnabotulinumtoxinA for Treatment of Chronic Migraine in Pediatric Age
by: Laura Papetti, et al.
Published: (2023-02-01)

Adverse Events of Intravesical Onabotulinum Toxin A Injection between Patients with Overactive Bladder and Interstitial Cystitis—Different Mechanisms of Action of Botox on Bladder Dysfunction?
by: Yuh-Chen Kuo, et al.
Published: (2016-03-01)

OnabotulinumtoxinA in chronic migraine: is the response dose dependent?
by: Ali Zandieh, et al.
Published: (2022-06-01)

OnabotulinumtoxinA for chronic migraine during pregnancy: a real world experience on 45 patients
by: Ho-Tin Wong, et al.
Published: (2020-10-01)

Effects of onabotulinumtoxinA treatment in patients with and without allodynia: results of the COMPEL study
by: William B. Young, et al.
Published: (2019-01-01)

Investigating Urine Biomarkers in Detrusor Underactivity and Detrusor Overactivity with Detrusor Underactivity Patients
by: Yuan-Hong Jiang, et al.
Published: (2023-04-01)

Persistence to anti-CGRP monoclonal antibodies and onabotulinumtoxinA among patients with migraine: a retrospective cohort study
by: Larry Charleston, et al.
Published: (2023-08-01)

Seminal papers in urology: two-year outcomes of Sacral Neuromodulation Versus OnabotulinumtoxinA for refractory urgency urinary incontinence: a Randomized Trial
by: Haidar Hadri bin Abd Wahab, et al.
Published: (2024-01-01)

OnabotulinumtoxinA: An Effective Tool in the Therapeutic Arsenal for Chronic Migraine With Medication Overuse
by: Edoardo Caronna, et al.
Published: (2018-10-01)

In Patients with Neurogenic Detrusor Overactivity and Hinman’s Syndrome: Would Intravesical Botox Injections Decrease the Incidence of Symptomatic Urinary Tract Infections
by: Banakhar M, et al.
Published: (2021-09-01)

Rehabilitation plus OnabotulinumtoxinA Improves Motor Function over OnabotulinumtoxinA Alone in Post-Stroke Upper Limb Spasticity: A Single-Blind, Randomized Trial
by: Deidre Devier, et al.
Published: (2017-07-01)

Safety and Effectiveness of OnabotulinumtoxinA in Patients with Laryngeal Dystonia: Final Report of a 52-Week, Multicenter Postmarketing Surveillance Study
by: Shigeomi Iimura, et al.
Published: (2023-09-01)

Urodynamic Detrusor Overactivity in Patients with Overactive Bladder Symptoms
by: Mohammed A. Al-Ghazo, et al.
Published: (2011-03-01)

OnabotulinumtoxinA Is an Effective Treatment for Chronic Migraine in Patients With Comorbid Fibromyalgia
by: María Sastre Real, et al.
Published: (2020-10-01)

The impact of onabotulinumtoxinA on severe headache days: PREEMPT 56-week pooled analysis
by: Manjit Matharu, et al.
Published: (2017-08-01)

Real-life use of onabotulinumtoxinA reduces healthcare resource utilization in individuals with chronic migraine: the REPOSE study
by: Katja Kollewe, et al.
Published: (2021-06-01)

Iron Deposits in Periaqueductal Gray Matter Are Associated with Poor Response to OnabotulinumtoxinA in Chronic Migraine
by: Clara Domínguez Vivero, et al.
Published: (2020-07-01)